RKDA — Arcadia Biosciences Share Price
0.000.00%
Last trade - 00:00- $6.82m
- $0.11m
- $5.33m
- 25
- 54
- 53
- 40
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.66 | ||
| Price to Tang. Book | 0.67 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.36 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -36.65% | ||
| Return on Equity | -22.48% | ||
| Operating Margin | -94.64% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.17 | 8.03 | 6.78 | 7.42 | 5.33 | 5.2 | 6.53 | 29.49% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Arcadia Biosciences, Inc. is a producer and marketer of plant-based health and wellness products. The Company’s product portfolio includes Zola Coconut Water (Zola). Zola is a natural, 100% coconut water. Zola is a non-genetically modified organisms (Non-GMO) project verified and only contains 60 calories per serving. It offers Zola in different varieties, such as Original, Slightly Sweetened; Original with Pulp, Slightly Sweetened; Espresso, Slightly Sweetened; Pineapple; Lime; and others. The recipe with Zola includes smoothies, desserts, cocktails and mocktails, and bowls.
Directors
- Kevin Comcowich NEC (53)
- Stanley Jacot PRE (52)
- Pamela Haley CFO (50)
- Brian Schaffer SVP
- Randall Shultz CTO (45)
- Laura Pitlik CMO (47)
- Belinda Yao VOP
- Albert Bolles IND (63)
- Deborah Carosella IND (64)
- Lilian Shackleford Murray IND (62)
- Gregory Waller IND (71)
- Amy Yoder IND (54)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- February 17th, 2015
- Public Since
- May 15th, 2015
- No. of Shareholders
- 38
- No. of Employees
- 21
- Sector
- Food & Tobacco
- Industry
- Consumer Defensives
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 1,364,940
- Address
- 202 Cousteau Place, Suite 105, DAVIS, 95618-7761
- Web
- https://arcadiabio.com/
- Phone
- +1 5307567077
- Auditors
- Deloitte & Touche LLP
Upcoming Events for RKDA
Q1 2025 Arcadia Biosciences Inc Earnings Release
Arcadia Biosciences Inc Annual Shareholders Meeting
Similar to RKDA
22nd Century
NASDAQ Capital Market
Agrify
NASDAQ Capital Market
Aquabounty Technologies
NASDAQ Capital Market
Baikang Biological group
NASDAQ Capital Market
Benson Hill
NASDAQ Capital Market
FAQ
What is the Arcadia Biosciences share price?
As of Today at 18:19 UTC, shares in Arcadia Biosciences are trading at $5.00. This share price information is delayed by 15 minutes.
How has the Arcadia Biosciences share price performed this year?
Shares in Arcadia Biosciences last closed at $5.00 and the price had moved by +81.16% over the past 365 days. In terms of relative price strength the Arcadia Biosciences share price has outperformed the S&P500 Index by +48.73% over the past year.
What are the analyst and broker recommendations for Arcadia Biosciences?
The overall consensus recommendation for Arcadia Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Arcadia Biosciences dividend yield?
Arcadia Biosciences does not currently pay a dividend.
Does Arcadia Biosciences pay a dividend?
Arcadia Biosciences does not currently pay a dividend.
When does Arcadia Biosciences next pay dividends?
Arcadia Biosciences does not currently pay a dividend.
How do I buy Arcadia Biosciences shares?
To buy shares in Arcadia Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Arcadia Biosciences?
As of the previous close price of $5.00, shares in Arcadia Biosciences had a market capitalisation of $6.82m.
Where are Arcadia Biosciences shares listed?
Here are the trading details for Arcadia Biosciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: RKDA
What kind of share is Arcadia Biosciences?
Based on an overall assessment of its quality, value and momentum Arcadia Biosciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Arcadia Biosciences share price forecast for 2025?
The analyst consensus target price for shares in Arcadia Biosciences is $9.00. That is 80% above the last closing price of $5.00.
Analysts covering Arcadia Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$1.40 for the next financial year.
Find out moreWhat is the trend in the Arcadia Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arcadia Biosciences. Over the past six months, its share price has outperformed the S&P500 Index by +49.6%.
As of the last closing price of $5.00, shares in Arcadia Biosciences were trading +54.62% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Arcadia Biosciences PE Ratio?
The Arcadia Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Arcadia Biosciences?
Arcadia Biosciences' management team is headed by:
- Kevin Comcowich - NEC
- Stanley Jacot - PRE
- Pamela Haley - CFO
- Brian Schaffer - SVP
- Randall Shultz - CTO
- Laura Pitlik - CMO
- Belinda Yao - VOP
- Albert Bolles - IND
- Deborah Carosella - IND
- Lilian Shackleford Murray - IND
- Gregory Waller - IND
- Amy Yoder - IND